Paul M, Gafter-Gvili A, Fraser A, Leibovici L
Department of Medicine E and Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, 49100, Israel.
Eur J Clin Microbiol Infect Dis. 2007 Nov;26(11):825-31. doi: 10.1007/s10096-007-0375-4.
A previous meta-analysis showed that quinolones administered for prophylaxis of infections among cancer patients reduced all-cause mortality. We extracted from the primary trials infection-related and all-cause mortality as reported and assessed the effect of quinolones on non-infection-related mortality through meta-analysis. Among trials comparing quinolones to placebo or no treatment, a significant reduction in non-infection-related mortality was observed (relative risk 0.54, 95% confidence interval 0.32-0.93, 15 trials, 3,320 patients). This finding might represent biased attribution of deaths to infection or might be compatible with an anti-cancer effect of quinolone antibiotics. We present further analyses addressing these possibilities.
一项先前的荟萃分析表明,给予癌症患者预防感染的喹诺酮类药物可降低全因死亡率。我们从原始试验中提取报告的感染相关死亡率和全因死亡率,并通过荟萃分析评估喹诺酮类药物对非感染相关死亡率的影响。在将喹诺酮类药物与安慰剂或不治疗进行比较的试验中,观察到非感染相关死亡率显著降低(相对风险0.54,95%置信区间0.32 - 0.93,15项试验,3320例患者)。这一发现可能代表死亡被偏向性归因于感染,或者可能与喹诺酮类抗生素的抗癌作用相符。我们进一步分析了这些可能性。